HYPHARM’S OPTIMA RANGE, A RESPONSE TO THE SUSTAINABILITY CHALLENGES OF THE RABBIT FARMING SECTOR

In January 2020, Hypharm launched its new product line whose selection criteria have concentrated on reliability, ease of use and performance.
The findings of the internal trials monitored by R&D engineers confirm female viability at 99.4% in the 1st cycle (1st AI), 92.2% in the 2nd cycle and 86.8% in the 3rd cycle, compared with 80% for the previous genetic material.
Besides the performance of this new female product range, its resilience provides
farmers greater breeding comfort with less intervention and speeds up the steps towards medication-free rearing, important for both human health and animal welfare.